曼恩凯德生物医疗宣布，美国食品药品监督管理局已批准更新其吸入式胰岛素产品Afrezza®的药品标签。此次标签更新关键内容包括：为正在接受每日多次注射或胰岛素泵餐时治疗、并计划转换使用Afrezza®的患者，提供了明确的起始剂量指导方案。这一重要进展有望优化临床用药实践，为糖尿病患者提供更清晰、便捷的治疗转换路径。
曼恩凯德生物医疗宣布，美国食品药品监督管理局已批准更新其吸入式胰岛素产品Afrezza®的药品标签。此次标签更新关键内容包括：为正在接受每日多次注射或胰岛素泵餐时治疗、并计划转换使用Afrezza®的患者，提供了明确的起始剂量指导方案。这一重要进展有望优化临床用药实践，为糖尿病患者提供更清晰、便捷的治疗转换路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.